OncoMune announced today that Chief Scientific Officer Anahit Ghochikyan, Ph.D. presented data which demonstrates unequivocally for the first time the ability of a cancer vaccine to induce tumor regression by targeting a novel class of proteins called "epigenetic regulators of transcription." The vaccine, OCM-111™, represents a unique approach to cancer therapy which causes the eradication of tumor cells while preventing their mutation to escape the vaccine's effect.
